Sermonix Pharmaceuticals, a privately held biopharmaceutical company focused on the development of female-specific oncology products, has completed a $26 million series A financing.
The round was led by the WILD Family Office, which manages the investments of entrepreneur Hans-Peter Wild. Other participants in the financing included experienced biopharmaceutical investors and executives Lodewijk de Vink, Richard DeSchutter and Anthony Wild, Sermonix non-executive chairman, among others.
The series A proceeds will be used to fund the enrollment and completion of the Phase 2 clinical trial of Sermonix’s lead investigational drug, lasofoxifene. The open-label, randomized, multi-center Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE, NCT03781063) study will assess the activity of oral lasofoxifene versus intramuscular fulvestrant for the treatment of postmenopausal women who have locally advanced or metastatic estrogen receptor-positive (ER+)/HER2- breast cancer with an ESR1 mutation.
